Girish Venkataraman to Rituximab
This is a "connection" page, showing publications Girish Venkataraman has written about Rituximab.
Connection Strength
0.092
-
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. J Clin Oncol. 2024 Feb 01; 42(4):467-480.
Score: 0.058
-
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016 Jun; 91(4):395-9.
Score: 0.034